Giulia Bononi

Dr. Giulia Bononi

Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2020 in Seminars in Cancer Biology
Verified
Journal Article
Closed access
BHBtissame El Hassouni
Btissame El Hassouni
CGCarlotta Granchi
Carlotta Granchi
AVAndrea Vallés-Martí
Andrea Vallés-Martí
ISI Gede Putu Supadmanaba
I Gede Putu Supadmanaba
Giulia BononiGiulia Bononi
Giulia Bononi
FMFilippo Minutolo
Filippo Minutolo

6 July 2022 in Seminars in Cancer Biology
Verified
Journal Article
Closed access
Giulia BononiGiulia Bononi
Giulia Bononi
SMSamuele Masoni
Samuele Masoni
VBValeria Di Bussolo
Valeria Di Bussolo
Tiziano TuccinardiTiziano Tuccinardi
Tiziano Tuccinardi
CGCarlotta Granchi
Carlotta Granchi
Filippo MinutoloFilippo Minutolo
Filippo Minutolo

4 February 2019 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CGCarlotta Granchi
Carlotta Granchi
MLMargherita Lapillo
Margherita Lapillo
SGSandra Glasmacher
Sandra Glasmacher
Giulia BononiGiulia Bononi
Giulia Bononi
CLCristina Licari
Cristina Licari
ACAndrea Chicca
Andrea Chicca

2 July 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
Giulia BononiGiulia Bononi
Giulia Bononi
Tiziano TuccinardiTiziano Tuccinardi
Tiziano Tuccinardi
FRFlavio Rizzolio
Flavio Rizzolio
CGCarlotta Granchi
Carlotta Granchi
Much of the experimental evidence in the literature has linked altered lipid metabolism to severe diseases such as cancer, obesity, cardiovascular pathologies, diabetes, and neurodegenerative diseases. Therefore, targeting key effectors of the dysregulated lipid metabolism may represent an effective strategy to counteract these pathological conditions. In this context, α/β-hydrolase domain (ABHD) enzymes represent an important and diversified family of proteins, which are involved in the complex environment of lipid signaling, metabolism, and regulation. Moreover, some members of the ABHD family play an important role in the endocannabinoid system, being designated to terminate the signaling of the key endocannabinoid regulator 2-arachidonoylglycerol. This Perspective summarizes the research progress in the development of ABHD inhibitors and modulators: design strategies, structure–activity relationships, action mechanisms, and biological studies of the main ABHD ligands will be highlighted.

31 July 2020 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
Giulia BononiGiulia Bononi
Giulia Bononi
DIDalila Iacopini
Dalila Iacopini
GCGaspare Cicio
Gaspare Cicio
SPSebastiano Di Pietro
Sebastiano Di Pietro
CGCarlotta Granchi
Carlotta Granchi
Filippo MinutoloFilippo Minutolo
Filippo Minutolo

1 September 2018 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Giulia BononiGiulia Bononi
Giulia Bononi
CGCarlotta Granchi
Carlotta Granchi
MLMargherita Lapillo
Margherita Lapillo
MGMassimiliano Giannotti
Massimiliano Giannotti
DNDaniela Nieri
Daniela Nieri
Tiziano TuccinardiTiziano Tuccinardi
Tiziano Tuccinardi